NEW YORK (GenomeWeb News) – BlueGnome will market Rubicon Genomics' technology along with its microarray-based aneuploidy chromosome screening and detection systems under a new non-exclusive agreement, Rubicon said today.
BlueGnome will market the PicoPlex technology to in vitro fertilization researchers under the name SurePlex DNA Amplification System. The PicoPlex technology can obtain "the same amount of genomic data from one cell as from 10,000," the company said, enabling researchers to produce five micrograms of amplified DNA in under three hours.
"We selected PicoPlex as the basis of SurePlex due to its rapid protocol, highly representative amplification and improved consistency over other amplification methods," Nick Haan, founder and CEO of BlueGnome, said in a statement.